Virax Biolabs Group Limited filed a Sticker Prospectus Supplement to increase the maximum aggregate offering amount of Ordinary Shares available for sale under its existing At The Market Offering Agreement with H.C. Wainwright & Co., LLC. The new limit is set at $2,070,060.20, which excludes $3,658,152 of shares previously sold under the program. This amendment supplements the original agreement dated January 22, 2024, and related prospectus supplements from December 2023 and September 2024. The filing includes a legal opinion regarding the legality of the issuance. Virax Biolabs Group Limited operates in the biotechnology industry, specializing in viral vector manufacturing for gene therapy and vaccine development.
